Novabay Pharmaceuticals Inc: Weathering Stock Market Storms with 0.94M Market Cap

Novabay Pharmaceuticals Inc’s market performance has been unstable in recent times. The company’s stock hit a 1-year high of $2.60 on 02/28/23 and a low of $0.12 for the same time frame on 02/07/24.

52-week price history of NBY Stock

Studying a stock’s 52-week price history, which includes both low and high prices, can help gauge its current status and potential future performance. Novabay Pharmaceuticals Inc’s current trading price is -94.48% away from its 52-week high, while its distance from the 52-week low is 16.75%. The stock’s price range during the 52-week period has remained between $0.12 and $2.60. In the Healthcare sector, the company’s shares saw a trading volume of around 2.29 million for the day, which was evidently higher than the average daily volume of 0.91 over the past three months.

#1 Small-Cap Uranium Stock for Ultra-Fast Gains in 2024

We've uncovered THE ONE small-cap uranium stock that has unearthed a near-surface, high-grade uranium discovery in the Saudi Arabia of Uranium — Canada's prolific Athabasca Basin. Best of all, this small-cap uranium stock is currently flying just below Wall Street's radar… giving you the early-entry opportunity around US$0.30 per share. But that won't last long. Drills are turning right now with results set to be released to the market very, very soon.

Learn all about it in this brand new FREE online report.

Market Capitalization and Financial Performance: An In-Depth Look

Novabay Pharmaceuticals Inc (NBY) has experienced a quarterly decline of -58.84% in its revenues when compared to the same period in the previous year. Presently, the company has a total market capitalization of 0.94M.

Making Sense of Trading Volume and Moving Average Data

Based on Barchart.com data, the company’s moving average over the 100-day period was 0.2893, with a change in price of -0.3164. Similarly, Novabay Pharmaceuticals Inc recorded 1,616,726 in trading volume during the last 100 days, posting a change of -68.78%.

Examining NBY’s Debt-to-Equity Ratio: What You Need to Know

The debt-to-equity (D/E) ratio is a crucial measure that sheds light on a company’s financial health and market standing. It is determined by dividing a company’s overall liabilities by its shareholders’ equity, showing the extent of a company’s debt usage in financing its assets compared to the shareholders’ equity. At the time of writing, the total D/E ratio for NBY stands at 0.43. Similarly, the long-term debt-to-equity ratio is also 0.18.

NBY Stock Stochastic Average

As of today, Novabay Pharmaceuticals Inc’s raw stochastic average for the last 50 days stands at 10.10%. This is a decline compared to the raw stochastic average of the previous 20 days, which was noted at 27.11%. Furthermore, the company’s Stochastic %K and %D values for the past 20 days were 30.66% and 23.31%, respectively.

NBY Stock Price Performance Analysis

The performance of the stock price over the year has been up and down, leaving investors with either an optimistic or pessimistic outlook, depending on how they interpret the data. The metric has seen a significant loss of -29.61% since the start of this calendar year. Looking back over the last six months, we can see a stronger performance of -78.77%. Over the past 30 days, the price of NBY has leaped by -13.10%. And in the last five days, it has fallen by -4.27%.

Leave a Reply

Your email address will not be published. Required fields are marked *

On Key

Related Posts